Showing results (341-350 of 352) with videos related to

Sort By:
Pageof 36
Emerging Infectious Diseases|January 25, 2024
Prevalence of SARS-CoV-2 Infection among Children and Adults in 15 US Communities, 2021Jessica Justman, Timothy Skalland, Ayana Moore, et al.
JAMA Network Open|May 28, 2025
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical TrialsLeah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Communications Medicine|April 17, 2026
Viral variant but not host factors associate with SARS-CoV-2 viral kineticsWilliam O Hahn, Leigh H Fisher, Amy Ward, et al.
Science (New York, N.Y.)|November 23, 2021
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trialPeter B Gilbert, David C Montefiori, Adrian B McDermott, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy TrialPeter B Gilbert, David C Montefiori, Adrian McDermott, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
The New England Journal of Medicine|November 27, 2024
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F Kelley, Maribel Acevedo-Quiñones, Allison L Agwu, et al.
Pageof 36